To classify the cerebral cavernous malformations and to investigate the natural history of cavernous malformations according to the classification, 41 patients with 61 cavernous malformations (40 cavernous malformations from 22 patients treated with gamma knife surgery) were regularly followed up using magnetic resonance (MR) imaging for a mean period of 25.5 months in treated cavernous malformations and 20
volume and developing after gamma knife surgery were defined as the adverse reaction of the irradiation. Moreover, the natural history of the lesions was also studied and correlated with clinical data in all patients.
Results
Sixty-one cavernous malformations were classified as follows: 17 in type I, 23 in type II, 10 in type III, and 11 in type IV (Table 1) . Of these 61 cavernous malformations, 27 cavernous malformations remained unchanged in size, and 26 cavernous malformations appeared to be decreased in size. Remaining eight cavernous malformations showed increase in size. Of 26 cavernous malformations which showed decrease in size, the signal-intensity changes of 22 cavernous malformations were consistent with the usual degradation of blood products, including the progressive disappearance of hyperintense areas on both T1-and T2-weighted images and subsequent residual area of decreased signal intensity on T2-weighted images (Fig. 2) . Remaining four cavernous malformations showed no signal intensity changes consistent with the usual degradation of blood products but showed decrease in size. The eight cavernous malformations with increase in size demonstrated changes in signal intensity on followup examinations with no concordance with the stage of hematoma evolution, that is, increase in size or concomitant signal-intensity changes consistent with hyperacute or acute hemorrhage. Of these eight cavernous malformations six were in Group I and two in Group II. These eight cavernous malformations were considered as rebleeding cases and six cavernous malformations occurred in type II, two in type III, but none in type I or IV. These eight cavernous malformations were six of intralesional hemorrhage and two of extralesional hemorrhage (Figs. 3 and 4). Number of cavernous malformations and rebleedings in each group are also illustrated in Table 1. Rebleedings were more frequent in type II than in other types (p=0.044).
However, there was no statistical significance between two groups in rebleeding rates (p=0.52). At initial examination 21 cavernous malformations showed perilesional edema on MR imaging. Seven cavernous malformations were in Group I and 14 lesions in Group II. One new cavernous malformation developed during follow-up period in a patient from Group I. This cavernous malformation was a type I cavernous malformation and was located at the occipital lobe.
Adverse reaction of irradiation was observed in five of 22 patients treated with gamma knife surgery. Four of these five patients exhibited regression of In our study, 27 of 61 cavernous malformations remained unchanged in size and signal intensity suggesting no changes in type of our classification. Of these 27 cavernous malformations, 20 were in Group I and seven in Group II. On the other hand, 26 cavernous malformations showed reduction in size during follow-up period. Of 26 cavernous malformations showing a decrease in size, 22 cavernous malformations demonstrated MR images consistent with the evolution of hemorrhage, and remaining four cavernous malformations only showed decrease in size. The reason for more number of lesions showing the usual evolution of hemorrhage in our results, compared with the report of Sigal et al., was thought to be due to our detailed classification of cavernous malformations.
In other words, we regarded the change of type from I to IV in our classification as the evolution of hemorrhage. Eight cavernous malformations demonstrated changes on follow-up examinations with no concordance with the stage of hematoma evolution, that is, increase in size or signal intensity changes suggesting rebleeding.
Of these eight cavernous malformations six were in Group I (6/40, 15.0%) and two in Group II (2/21, 9.5%). However, there was no statistical significance between these two groups in rebleeding rates (p=0.52).
In 
